Singapore: Eisai published the results of its 'adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304' online in the July 25, 2012, edition of Neurology, which is the medical journal of the American Academy of Neurology.

The US FDA and the European Medicines Agency are presently reviewing the marketing authorization applications for perampanel. Perampanel is an orally administered, highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, discovered and being developed by Eisai.

This month has been very eventful for Eisai considering the fact that it entered in a research collaboration with Verastem for the development of next-generation of small molecule Wnt inhibitors. Eisai also announced preliminary results of phase III study of Halaven (eribulin mesylate) Injection that is used to treat locally advanced or metastatic breast cancer.